Lancet Regional Health-Europe最新文献

{"title":"The 2026 EU–India free trade agreement: why it matters for global health and trade","authors":"Astrid Berner-Rodoreda, Pramiti Parwani, Chetali Rao, Emmanuel André, Günter Fröschl, Jolene Skordis, Sangeeta Sharma, Quique Bassat, Rifat Atun, Milena Vainieri, Andrew Farlow, Fabrizio Tediosi, Raffaella Ravinetto, Khaled M. Ismail, Elil Renganathan, Anniek de Ruijter, Tim Taylor, Gorik Ooms, Eldrid Herrington, Gopal Dabade, Katrina Perehudoff","doi":"10.1016/j.lanepe.2026.101794","DOIUrl":"10.1016/j.lanepe.2026.101794","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101794"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148657221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attention-Deficit/Hyperactivity Disorder in Children and Adults in England, 2000–2025: Recorded Prevalence and Diagnostic Trends in a Population-Based Observational Study Using Routinely Collected Primary Care Data","authors":"Amber John,&nbsp;Gavin R. Stewart,&nbsp;William Mandy,&nbsp;Celine El Baou,&nbsp;Elizabeth O’Nions,&nbsp;Lucy Corrigan,&nbsp;Henry Shelford,&nbsp;Rob Saunders,&nbsp;Douglas G.J. McKechnie,&nbsp;Jae Won Suh,&nbsp;Georgia Pavlopoulou,&nbsp;Philip Asherson,&nbsp;Jessica Agnew-Blais,&nbsp;Josh Stott","doi":"10.1016/j.lanepe.2026.101740","DOIUrl":"10.1016/j.lanepe.2026.101740","url":null,"abstract":"<div><h3>Background</h3><div>Over recent years, public awareness of ADHD has increased, alongside a rise in assessment referrals. There is urgent need for large-scale evidence on the prevalence and incidence of recorded ADHD to understand diagnostic coverage in England.</div></div><div><h3>Methods</h3><div>Data were used from CPRD Aurum, a large longitudinal database of records from primary care practices across England. Point prevalence of recorded ADHD was estimated at a fixed index date (30.06.2025). Estimates of ADHD population prevalence from previous research were used as reference values to contextualise recorded diagnosis rates. Crude incidence of recorded ADHD per 1000 person-years was calculated overall. Annual incidence over the study period (2000–2024) was also calculated to understand trends in ADHD recording over time.</div></div><div><h3>Findings</h3><div>Data from 3,536,476 to 42,241,788 patients were used for prevalence and incidence analyses respectively. Point prevalence of recorded ADHD was 1.19% (95%CI = 1.18–1.21), with higher prevalence in males than females, and decreasing prevalence with age. Comparisons of these estimates with documented population prevalence of ADHD showed that ADHD diagnosis rates in England remain substantially lower than published estimates of prevalence. The gap between recorded diagnosis rates and published reference prevalence estimates varied across groups, ranging from 28.71% (males aged 18–24) to 93.51% (males and females aged 65+). Crude incidence of recorded ADHD was 0.61 per 1000 person-years (95%CI = 0.61–0.61). Annual incidence rates increased markedly over the study period, with an acceleration of ADHD recording from 2020. Highest incidence was observed in males aged &lt;18, and lowest incidence was in males and females aged 65+, for whom rates of ADHD remained stable and low across follow-up.</div></div><div><h3>Interpretation</h3><div>Findings provide a detailed picture of current diagnostic coverage and temporal change. Results indicate that although ADHD diagnoses have increased substantially over the past decade, recorded ADHD diagnosis rates in England remain substantially lower than published estimates of ADHD prevalence, particularly in older age, suggesting potential under-recognition. Findings highlight an urgent need for diagnostic services that are accessible across the lifespan and adequately resourced to meet need.</div></div><div><h3>Funding</h3><div>Medical Research Foundation (MRF-RGM-MH-24-114); British Academy (PFSS23∖230043).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101740"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of the Dengue Vaccine TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain","authors":"Daniel Camprubí–Ferrer,&nbsp;Cesc Bertran–Cobo,&nbsp;Lluís Valerio,&nbsp;Meritxell Saloni,&nbsp;Isabel González Nieto,&nbsp;Victoria López López,&nbsp;David Garcia,&nbsp;Elisabet Jurado,&nbsp;Maria Luisa Machado,&nbsp;Daniela Pérez–León,&nbsp;Sarai Cuevas Marín,&nbsp;Carme Subirà,&nbsp;Judit Villar–García,&nbsp;Dolores Herena García,&nbsp;Susana Nuria Ayala Cortés,&nbsp;Maria Sànchez Casado,&nbsp;Aina Gomila–Grange,&nbsp;Claudia Flores,&nbsp;Natalia Morales Llorente,&nbsp;Ester Górriz Hidalgo,&nbsp;José Muñoz","doi":"10.1016/j.lanepe.2026.101727","DOIUrl":"10.1016/j.lanepe.2026.101727","url":null,"abstract":"<div><h3>Background</h3><div>TAK-003 is the first dengue vaccine licensed for endemic and non-endemic regions, but real-world safety data in non-endemic travel settings are scarce, particularly for older adults, people with comorbidities, and concomitant vaccinations.</div></div><div><h3>Methods</h3><div>We conducted a prospective multicentre pharmacovigilance study in eight Spanish travel clinics, enrolling travellers aged ≥4 years who received TAK-003 (January–December 2024). Participants were followed for adverse events (AEs) after each dose. Logistic regression models assessed associations of age, sex, comorbidities, prior flaviviral infection or vaccination history, and concomitant vaccination with risks of any, systemic, or local AEs.</div></div><div><h3>Findings</h3><div>Among 1028 participants (1851 TAK-003 doses), 998 (97.1%) completed ≥1 follow-up assessments; 587/998 (58.8%, 95% CI 55.7–61.8) reported AEs. After the first dose, 470/998 (47.1%, 44.0–50.2) reported AEs, most often injection site pain and swelling, headache, or malaise, declining to 235/679 (34.6%, 31.1–38.3) after the second dose. No serious AEs, anaphylaxis, or deaths occurred. Female sex was associated with any AEs (adjusted OR 1.83, 95% CI 1.42–2.37) and local AEs (1.89, 1.44–2.48). Prior dengue was associated with any (1.51, 1.07–2.14) and systemic AEs (1.73, 1.22–2.43). Concomitant flaviviral vaccination was associated with higher odds of systemic AEs (1.64, 1.18–2.28). Age ≥60 years and comorbidities were not associated with increased reactogenicity.</div></div><div><h3>Interpretation</h3><div>TAK-003 was well tolerated in travellers from non-endemic regions, with no serious AEs reported. Female sex, prior DENV infection, and flaviviral vaccine co-administration were associated with increased reactogenicity; older age, comorbidities, and non-flaviviral vaccine co-administration were not. These findings provide real-world evidence on tolerability of TAK-003 in travellers from non-endemic regions. Larger studies with extended follow-up are needed to better characterise uncommon and longer-term AEs.</div></div><div><h3>Funding</h3><div>No dedicated funding.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101727"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Spatiotemporal dynamics of leptospirosis in Europe: a retrospective observational study with prospective projections” The Lancet Regional Health – Europe, Volume 65, June 2026, 101671","authors":"Angela Fanelli,&nbsp;Baptiste Alglave,&nbsp;Luca Caporaso,&nbsp;Alessandro Cescatti,&nbsp;Juan-Carlos Ciscar,&nbsp;Gregoire Dubois,&nbsp;Alessandro Dosio,&nbsp;Rosa M. Estevez-Reboredo,&nbsp;María Blazquez,&nbsp;Dolores Ibarreta,&nbsp;Andrea Mandrici,&nbsp;Emanuele Massaro,&nbsp;Rachel Lowe,&nbsp;Wojtek Szewczyk","doi":"10.1016/j.lanepe.2026.101790","DOIUrl":"10.1016/j.lanepe.2026.101790","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101790"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148635246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical effectiveness of internet-delivered self-help Aacceptance and Commitment Therapy for family carers of people with dementia (iACT4CARERS): a multicentre, parallel, randomised controlled trial","authors":"Naoko Kishita,&nbsp;Rebecca L. Gould,&nbsp;Mizanur Khondoker,&nbsp;Lance M. McCracken,&nbsp;Megan Riggey,&nbsp;Ana Paula Trucco,&nbsp;David Howe,&nbsp;Abbey Couchman,&nbsp;Emma Flanagan,&nbsp;Ramesh Vishwakarma,&nbsp;Cecile Guillard,&nbsp;Polly-Anna Ashford,&nbsp;David Turner,&nbsp;Andrés Losada-Baltar,&nbsp;Isabel Cabrera-Lafuente,&nbsp;Laura Gallego-Alberto,&nbsp;Erica Richmond,&nbsp;Barbara Czyznikowska,&nbsp;Matthew Hammond,&nbsp;Aditya Nautiyal,&nbsp;Morag Farquhar","doi":"10.1016/j.lanepe.2026.101766","DOIUrl":"10.1016/j.lanepe.2026.101766","url":null,"abstract":"<div><h3>Background</h3><div>As dementia prevalence rises globally, unpaid family carers provide most care and face high mental health risk. Existing psychological interventions offer limited benefit for anxiety in this population. We evaluated the effectiveness of an internet-delivered, self-help Acceptance and Commitment Therapy intervention with minimal non-expert therapist support (iACT4CARERS) to reduce anxiety in dementia family carers.</div></div><div><h3>Methods</h3><div>We conducted a multi-site, single-blind, parallel-group, randomised controlled trial across UK national healthcare services. Eligible participants were family carers of a person with dementia and reported anxiety symptoms (Generalised Anxiety Disorder-7 [GAD-7] score ≥5). Participants were allocated (1:1) to iACT4CARERS plus treatment-as-usual or treatment-as-usual alone, using computer-generated randomisation with minimisation by ethnicity and baseline anxiety. The intervention comprised an eight-session self-help programme guided by non-expert therapists. Outcome assessors and the lead statistician were blinded to allocation. The primary outcome was anxiety symptoms, assessed using the GAD-7 at 12-weeks post-randomisation. Analyses followed the intention-to-treat principle using linear regression models. The trial was pre-registered with ISRCTN (45995725).</div></div><div><h3>Findings</h3><div>Between November 1, 2023, and January 14, 2025, 902 individuals were referred: 567 (63%) were assessed for eligibility and 496 (87%) were randomised (249 to intervention; 247 to control). 397/496 (80%) were female. Primary outcome data were available for 398/496 participants (80%). After adjustment for baseline anxiety, ethnicity, and education, iACT4CARERS plus treatment-as-usual significantly reduced anxiety at 12 weeks compared with treatment-as-usual alone (adjusted mean difference −2.62, 95% CI −3.47 to −1.77; p &lt; 0.0001; d = 0.53), with participants in the intervention group showing clinically meaningful improvement. Three non-intervention-related adverse events were reported; no serious adverse events occurred.</div></div><div><h3>Interpretation</h3><div>iACT4CARERS is an effective intervention for reducing anxiety symptoms and addressing a major unmet mental health need in this population, with strong potential for scalable implementation.</div></div><div><h3>Funding</h3><div>National Institute for Health and Care Research Health Technology Assessment.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101766"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial","authors":"Juul M.P.A. van den Reek,&nbsp;Charlotte A.M. van Riel,&nbsp;Rani Soenen,&nbsp;Anke Eylenbosch,&nbsp;Lisa Schots,&nbsp;Lara S. van der Schoot,&nbsp;Lynda Grine,&nbsp;Gerjon Hannink,&nbsp;Fabienne Willaert,&nbsp;Tom Hillary,&nbsp;Paula P.M. van Lümig,&nbsp;Pierre-Dominique Ghislain,&nbsp;Paul M. Ossenkoppele,&nbsp;Sven Lanssens,&nbsp;Bas S.P. Prens,&nbsp;Linda Temmerman,&nbsp;Martijn B.A. van Doorn,&nbsp;Ella A.M. van der Voort,&nbsp;Inge Haeck,&nbsp;Janneke Huizinga,&nbsp;Elke M.G.J. de Jong","doi":"10.1016/j.lanepe.2026.101721","DOIUrl":"10.1016/j.lanepe.2026.101721","url":null,"abstract":"<div><h3>Background</h3><div>Interleukin (IL)17 and IL23 inhibitors (i) for psoriasis are highly effective but not all patients may need the registered dose. Dose reduction (DR) could contribute to prevent unnecessary drug exposure and lower healthcare expenditures. The aim of this study was to evaluate whether DR through stepwise interval prolongation is effective and safe in patients with psoriasis with stable low disease activity.</div></div><div><h3>Methods</h3><div>This pragmatic, open-label, controlled, non-inferiority randomised clinical trial was performed in 19 (non-)academic hospitals in the Netherlands and Belgium. Patients were randomised (2:1) to stepwise DR or usual care (UC) by block randomisation with random allocation sequence, stratified by biologic. Patients with stable low disease activity on registered dosages of IL17i (secukinumab, ixekizumab, bimekizumab, brodalumab) or IL23i (guselkumab, risankizumab, tildrakizumab) were eligible. In DR, injection intervals were prolonged stepwise to 67.0% and 50.0% of the original dose if disease activity permitted. The primary aim was to assess non-inferiority of this DR strategy compared to UC regarding the incidence proportion of persistent flares (Psoriasis Area and Severity Index (PASI) &gt; 5 for ≥3 months) after 18 months, with a non-inferiority margin of 15.0%. Patients were analysed by intention-to-treat (ITT) and per-protocol (PP) with imputation of missings. <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> Identifier <span><span>NCT04340076</span><svg><path></path></svg></span>; status: closed.</div></div><div><h3>Findings</h3><div>Between June 30, 2020 and September 14, 2023, 244 patients were included (mean age 51 ± 15 years; 67.0% male; DR N = 164, UC N = 80). After 18 months, a difference of 2.4% (95% CI −2.0% to 6.8%) in incidence proportion of persistent flares (DR (4.0%) and UC (1.6%) in ITT) showed non-inferiority of DR. No serious adverse events/deaths related to DR were reported.</div></div><div><h3>Interpretation</h3><div>Disease-activity guided, stepwise interval prolongation of IL17i and IL23i in patients with controlled psoriasis is an effective and safe strategy to reduce unnecessary exposure to these expensive drugs.</div></div><div><h3>Funding</h3><div>ZonMw (the Netherlands Organization for Health Research and Development), KCE Trials (the Belgian Health Care Knowledge Centre).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101721"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists in type 1 diabetes: expanding the therapeutic landscape beyond insulin","authors":"George D. Dimitriadis,&nbsp;Vaia Lambadiari","doi":"10.1016/j.lanepe.2026.101782","DOIUrl":"10.1016/j.lanepe.2026.101782","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101782"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13416622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148621890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis” The Lancet Regional Health – Europe, Volume 60, January 2026, 101524","authors":"Célia Dupain,&nbsp;Nicolas Jacquin,&nbsp;Aurélien Latouche,&nbsp;Zoé Nevière,&nbsp;Pierre Gestraud,&nbsp;Abderaouf Hamza,&nbsp;Kenza Nedara,&nbsp;Vincent Cockenpot,&nbsp;Janick Selves,&nbsp;Yves Allory,&nbsp;Laetitia Chanas,&nbsp;Maud Milder,&nbsp;Isabelle Soubeyran,&nbsp;Hélène Blons,&nbsp;Anna Patrikidou,&nbsp;Axel de Bernardi,&nbsp;Julien Masliah-Planchon,&nbsp;Odette Mariani,&nbsp;Etienne Rouleau,&nbsp;Fabienne Escande,&nbsp;Sarah Watson","doi":"10.1016/j.lanepe.2026.101789","DOIUrl":"10.1016/j.lanepe.2026.101789","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101789"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13416621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Europe's failure to deliver on drug-resistant tuberculosis","authors":"The Lancet Regional Health – Europe","doi":"10.1016/j.lanepe.2026.101813","DOIUrl":"10.1016/j.lanepe.2026.101813","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101813"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Metabolic trajectories before diabetes diagnosis across subgroups: a pooled analysis of prospective European cohort studies’ [The Lancet Regional Health—Europe volume 66 (2026) 1–11/101715]","authors":"Liisa Hakaste,&nbsp;Mette K. Andersen,&nbsp;Lars Ängquist,&nbsp;Haifa Maalmi,&nbsp;Jagadish Vangipurapu,&nbsp;Türküler Cakmak,&nbsp;Anna Möllsten,&nbsp;Björn Tavelin,&nbsp;Mikko Lehtovirta,&nbsp;Most Champa Begum,&nbsp;Rashmi B. Prasad,&nbsp;Annette Peters,&nbsp;Barbara Thorand,&nbsp;Allan Linneberg,&nbsp;Markku Laakso,&nbsp;Olov Rolandsson,&nbsp;Bjørn Olav Åsvold,&nbsp;Valeriya Lyssenko,&nbsp;Peter M. Nilsson,&nbsp;Christian Herder,&nbsp;Tiinamaija Tuomi","doi":"10.1016/j.lanepe.2026.101793","DOIUrl":"10.1016/j.lanepe.2026.101793","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"67 ","pages":"Article 101793"},"PeriodicalIF":15.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13416620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}